Jason M. Hafron, MD, discusses IsoPSA, a novel prostate-specific antigen assay for patients with a PSA > 4ng/ml who are facing a decision on prostate biopsy.
Jason M. Hafron, MD, CMO
Advertisement
Jason Hafron, MD, serves as the Chief Medical Officer at Michigan Institute of Urology.
Articles by Jason M. Hafron, MD, CMO
Oncologists at AUA 2025 share promising data, including sasanlimab, cretostimogene grenadenorepvec, and TAR-200 in NMIBC.
Jason M. Hafron, MD, CMO, discusses recent approvals in the non–muscle-invasive bladder cancer space and data from several clinical trials evaluating agents for bladder cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
ESMO 2026: Survival Gains and New Treatment Strategies in GI Cancers
3
FDA Approves Talazoparib/Enzalutamide in HRR-Mutated Prostate Cancer
4
ADCs Shine, Mixed Bag for Immunotherapy at ESMO 2026 Presidential Symposium III
5